Skin-on-Chip and clinical evaluation of the soothing potential of a topical natural treatment for atopic-prone skin: An exploratory study

Itch is the most common symptom of various dermatological disorders and can negatively impact patients' quality of life, especially when linked to chronic conditions such as dry skin and atopic dermatitis. While the specific mechanism of pruritus remains unclear, a decline in skin barrier function and release of key mediators of itch signaling are believed to play a pivotal role in itch stimulus. While topical corticosteroids are widely used to alleviate pruritus by suppressing inflammation, long-term use is limited by side effects, including skin atrophy. This study investigates the soothing potential of an innovative natural emulsion (NF). We used MIVO® skin-on-chip model to assess LTB₄ release after substance P stimulation, a key mediator in itch signaling. We found that NF effectively reduced LTB₄ secretion to a level comparable to that achieved with a corticosteroid product. Additionally, a cohort of subjects with skin prone to atopy (itchy, dry, and subject to recurrent erythema) was recruited to assess clinical efficacy and tolerability of NF. Compared to baseline, treatment with NF improved barrier function, skin hydration and erythema. Additionally, all participants reported an improvement in itching sensation after treatment. Collectively, these findings suggest that topical treatment with NF has the potential to mitigate itch-related inflammatory responses and skin barrier disorders.